<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405911</url>
  </required_header>
  <id_info>
    <org_study_id>0431-105</org_study_id>
    <nct_id>NCT01405911</nct_id>
  </id_info>
  <brief_title>Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)</brief_title>
  <official_title>A Phase II, Randomized, Placebo-Controlled, Parallel-group, Double-Blind, Dose Response Finding Clinical Trial to Study the Efficacy and Safety of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance Who Have Inadequate Glycemic Control on Diet/Exercise Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin
      (MK-0431/ONO-5435) used once daily (qd) for Japanese subjects with impaired glucose tolerance
      who have inadequate glycemic control using diet and exercise therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2011</start_date>
  <completion_date type="Actual">April 9, 2012</completion_date>
  <primary_completion_date type="Actual">April 9, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in glucose total area under the concentration curve (AUC) for meal tolerance test (MTT)</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in Glucose total AUC for 75g oral glucose tolerance test (OGTT)</measure>
    <time_frame>Baseline and Week 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 25 mg</intervention_name>
    <description>1 tablet orally once daily before breakfast for 8 weeks</description>
    <arm_group_label>Sitagliptin 25 mg</arm_group_label>
    <other_name>MK-0431/ONO-5435</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 50 mg</intervention_name>
    <description>1 tablet orally once daily before breakfast for 8 weeks</description>
    <arm_group_label>Sitagliptin 50 mg</arm_group_label>
    <other_name>MK-0431/ONO-5435</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Sitagliptin 25 mg</intervention_name>
    <description>1 tablet orally once daily before breakfast for 8 weeks</description>
    <arm_group_label>Sitagliptin 25 mg</arm_group_label>
    <arm_group_label>Sitagliptin 50 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Sitagliptin 50 mg</intervention_name>
    <description>1 tablet orally once daily for 8 weeks</description>
    <arm_group_label>Sitagliptin 25 mg</arm_group_label>
    <arm_group_label>Sitagliptin 50 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance

          -  On diet/exercise therapy

          -  Unlikely to conceive

          -  Meets all of the following glycemic parameters: Hemoglobin A1c (Japan Diabetes Society
             value) &lt;6.1%, Fasting Plasma Glucose &lt;126 mg/dL, and 2-hr plasma glucose level in 75g
             oral glucose tolerance test â‰¥140 mg/dL and &lt;200 mg/dL

        Exclusion Criteria:

          -  History of diabetes mellitus

          -  Disease or condition of clear or likely glucose tolerance disorder

          -  Previously treated with a drug to prevent diabetes and/or any antihyperglycemic drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <reference>
    <citation>Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab. 2015 Nov;17(11):1033-41. doi: 10.1111/dom.12507. Epub 2015 Jul 17.</citation>
    <PMID>26094974</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

